Next Article in Journal
Listeria monocytogenes Biofilms in the Food Industry: Is the Current Hygiene Program Sufficient to Combat the Persistence of the Pathogen?
Next Article in Special Issue
Coordinated Expression of HPV-6 Genes with Predominant E4 and E5 Expression in Laryngeal Papilloma
Previous Article in Journal
Adjunct Culture of Non-Starter Lactic Acid Bacteria for the Production of Provola Dei Nebrodi PDO Cheese: In Vitro Screening and Pilot-Scale Cheese-Making
Previous Article in Special Issue
G Protein-Coupled Receptor Genes, PTGDR1, PTGDR2, and PTGIR, Are Candidate Epigenetic Biomarkers and Predictors for Treated Patients with HPV-Associated Oropharyngeal Cancer
Review

Chronic Active Epstein–Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods

by 1,2
1
Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan
2
Department of Hematological Therapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo 113-8510, Japan
Microorganisms 2021, 9(1), 180; https://doi.org/10.3390/microorganisms9010180
Received: 25 December 2020 / Revised: 13 January 2021 / Accepted: 14 January 2021 / Published: 15 January 2021
(This article belongs to the Special Issue Pathogenic Role of Virus Infection in Head and Neck Tumors)
Chronic active Epstein–Barr virus infection (CAEBV) is a disease where Epstein–Barr virus (EBV)-infected T- or NK-cells are activated and proliferate clonally. The symptoms of this dual-faced disease include systemic inflammation and multiple organ failures caused by the invasion of infected cells: inflammation and neoplasm. At present, the only effective treatment strategy to eradicate EBV-infected cells is allogeneic stem cell transplantation. Lately, the investigation into the disease’s pathogenic mechanism and pathophysiology has been advancing. In this review, I will evaluate the new definition in the 2017 WHO classification, present the advancements in the study of CAEBV, and unfold the future direction. View Full-Text
Keywords: systemic chronic active Epstein–Barr virus infection; cutaneous chronic active Epstein–Barr virus infection; EBV-positive T-cell lymphoma of childhood; WHO classification systemic chronic active Epstein–Barr virus infection; cutaneous chronic active Epstein–Barr virus infection; EBV-positive T-cell lymphoma of childhood; WHO classification
Show Figures

Figure 1

MDPI and ACS Style

Arai, A. Chronic Active Epstein–Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods. Microorganisms 2021, 9, 180. https://doi.org/10.3390/microorganisms9010180

AMA Style

Arai A. Chronic Active Epstein–Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods. Microorganisms. 2021; 9(1):180. https://doi.org/10.3390/microorganisms9010180

Chicago/Turabian Style

Arai, Ayako. 2021. "Chronic Active Epstein–Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods" Microorganisms 9, no. 1: 180. https://doi.org/10.3390/microorganisms9010180

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop